摘要目的 探讨非小细胞肺癌(NSCLC)组织窖蛋白1与pERK1/2的表达及其与预后的关系.方法 应用免疫组织化学(sP法)检测160例NSCLC及20例正常肺组织标本中窖蛋白1与pERK1/2的表达.结果 窖蛋白1在NSCLC和正常肺组织阳性率分别为65.6%(105/160)和100%(20120),P=0.002.中-高分化组和低分化组阳性率分别为56.8%(46/81)和75.7%(53/70),P=0.015;Ⅰ-Ⅱ期阳性率为58.2%(53/91),Ⅲ-Ⅳ期阳性率75.4%(52/69),P=0.024;有淋巴结转移组阳性率为77.8%(56/72),无淋巴结转移组阳性率为55.7%(49/88),P=0.003.窖蛋白1阳性患者1、3、5年生存率(71.4%、37.1%、17.1%)低于阴性患者(89.1%、69.1%、43.6%),P=0.000.pERK1/2在NSCLC和正常肺组织阳性率分别为61.3%和0,P=0.000;中-高分化组和低分化组阳性率分别为53.1%(43/81)和71.4%(50/70),P=0.021;Ⅰ-Ⅱ期阳性率为49.5%(45/91),Ⅲ-Ⅳ期阳性率76.8%(53/69),P=0.000;有淋巴结转移组阳性率为80.6%(58/72),无淋巴结转移组阳性率为45.5%(40/88),P=0.000.pEBK1/2阳性患者1、3、5年生存率(74.5%、42.9%、19.4%)低于阴性者(82.3%、56.5%、37.1%),P=0.002.窖蛋白1与pERK1/2负相关,P=0.000.结论 窖蛋白1在NSCLC中低表达,pEBK1/2在NSCLC中高表达.窖蛋白1蛋白阳性表达和pEBK1/2蛋白高表达与NSCLC的发生及侵袭、转移相关.窖蛋白1和pERK1/2可作为NSCLC一个预后预测的指标.

abstractsObjective To study the relationship between expression of caveolin-1(Car-1) and pERK1/2 and prognosis in non-small cell lung cancer (NSCLC). Methods Car-1 and pERK1/2 protein expression was assessed by immunohistocbemistry in samples obtained from 160 patients with NSCLC and 20 patients with normal lung tissue. Results Normal bronchial and alveolar epithelial cells were positive for Cav-1(membranous and cytoplasmic staining patterns). The expression rate of Car-1 in NSCLC was 65.6%(105/160), which was significantly lower than that in normal lung tissue (P=0.002). The Cav-1-positive rates in well to moderately differentiated tumors and poorly diferentiated tumors were 56.8% (46/81) and 75.7% (53/70), respectively (P=0.015). The expression of Car-1 was much higher in patients with lymph node metastasis (77. 8%, compared with 55.7% in lymph node-negative group,P=0.003). The expression was also higher in stage Ⅲ to Ⅳ than in stage Ⅰ to Ⅱ disease (75.4%, compared with 58.2% ,P=0.024). The overall survival of patients with Gay-1-positive tumors (71.4%, 37.1% and 17.1% 1-, 3- and 5-year survival, respectively) was lower than those with Gay-1-negative tumors (89.1%, 69.1% and43.6% 1-, 3- and 5-year survival, respectively,P=0.000). On the other hand, normal bronchial and alveolar epithelial cells were negative for pERK1/2. The expression rate of pERK1/2 in NSCLC was 61.3%, which was significandy higher than that in normal lung tissues (P=0.000). The pERK1/2.positive rates in well to moderately differentiated tumors and poorly differentiated tumors Was 53.1%and 71.4%.respectively(P=0.021).rnle expression of pERKl/2 Was much higher in patients with lymph node metastasis(80.6%,compared with 45.5% in lymph node-negative group,P=0.000). The expression of pERK1/2 Was also hii er in stage Ⅲ to Ⅳ than in stage Ⅰ to Ⅱ disease(76.8%, compared with 49.55,P=0.426).The overall survival of patients with pERK1/2-positive tumors (74.5%,42.9% and 19.4% 1-,3- and 5-year survival,respectively)wag lower than those with pERK1/ 2-negative tumors(82.3%,56.5% and 37.1%1-,3- and 5-year survival,respectively,P=0.002). Cav-1 and pERK1/2 expression showed negative correlation(P=0.000).Condusiom Car-1 expression is lower in NSCLC than in normal lung tissue,whereas pERKl/2 expression is higher in NSCLC.Positive expression of Cav-1 and overexpression of pERK1/2 correlates witll tumorigenesis and tumor progression of NSCLC.Cav-1 and pERK1/2 may serve as potential markers for predicting prognosis in NSCLC.